TriSalus Life Sciences Appoints Richard Marshall, M.D., as Chief Medical Officer
TriSalus Life Sciences, Inc. (TLSI)
Company Research
Source: Business Wire
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces the appointment of Richard Marshall, M.D., as Chief Medical Officer on a full-time basis, effective June 29, 2026. Dr. Marshall will transition into the role from his current position as Medical Director, a role he has held since January 2025. In his new capacity, he will lead the Company’s medical strategy and provide clinical leadership across development, evidence generation and broader strategic initiatives.“Dr. Marshall brings a rare combination of frontline clinical insight and deep interventional oncology expertise that is uniquely aligned with our mission. Since joining TriSalus as Medical Director, he has been an invaluable clinical voice in driving the expansion of our TriNa
Show less
Read more
Impact Snapshot
Event Time:
TLSI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TLSI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TLSI alerts
High impacting TriSalus Life Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
TLSI
News
- TriSalus Life Sciences (TLSI) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting [Yahoo! Finance]Yahoo! Finance
- TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific MeetingBusiness Wire
- TriSalus Life Sciences Announces Publication Demonstrating Enhanced Delivery and Immune Activation with Nelitolimod Delivered with Pressure-Enabled Drug Delivery in Liver Tumor ModelsBusiness Wire
- Canaccord Lowers its Price Target on TriSalus Life Sciences, Inc. (TLSI) to $7 from $12 and Maintains a Buy Rating [Yahoo! Finance]Yahoo! Finance
TLSI
Earnings
- 3/5/26 - Miss
TLSI
Sec Filings
- 4/7/26 - Form 8-K
- 4/1/26 - Form 4
- 3/31/26 - Form ARS
- TLSI's page on the SEC website